Angioedema is the medical condition characterized by swelling of the lower layer of skin and tissue just under the skin or mucous membrane occurs. There are four main type of angioedema namely allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema (HAE). Angioedema is caused by various factors and in most of the cases exact cause is unknown. Major cause of angioedema are allergic reaction, adverse effect of any medication, genetic defects, and infections.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1371

Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global angioedema treatment market

In 2017, U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients. In 2014, Pharming Group NV and Salix Pharmaceuticals, Ltd. received US Food and Drug Administration (FDA) approval for RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, indicated for the treatment of acute angioedema attacks in adult and adolescent patients with HAE. In 2016, CSL Behring received FDA approval for Berinert [C1 Esterase Inhibitor (Human)], indicated for the treatment of HAE attacks in pediatric patients. These multiple approvals of new drugs by regulatory bodies are expected to drive growth of global angioedema treatment market over the forecast period.
Angioedema Treatment Market Key Players:-

Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.

Request Customization: https://www.coherentmarketinsights.com/insight/request-customization/1371

Angioedema Treatment Market Taxonomy:

The angioedema treatment market is segmented on the basis of condition type, drug type, route of administration, distribution channel, and geography

By Condition Type:
• Allergic angioedema
• Drug-induced angioedema
• Idiopathic angioedema
• Hereditary angioedema (HAE)
By Drug Type:
• C1 esterase inhibitor
◦ Cinryze
◦ Berinert
◦ Ruconest
◦ Haegarda
• Selective bradykinin B2 receptor antagonist
◦ Firazyr
• Kallikrein inhibitor
◦ Kalbitor
• Others
By Route of Administration:
• Injection
◦ Intravenous
◦ Subcutaneous
• Oral
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online pharmacies

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]